• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不可逆性缺损区域的铊摄取情况。再次注射后铊活性的变化幅度可区分存活心肌与无存活心肌。

Regional thallium uptake in irreversible defects. Magnitude of change in thallium activity after reinjection distinguishes viable from nonviable myocardium.

作者信息

Dilsizian V, Freedman N M, Bacharach S L, Perrone-Filardi P, Bonow R O

机构信息

Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.

出版信息

Circulation. 1992 Feb;85(2):627-34. doi: 10.1161/01.cir.85.2.627.

DOI:10.1161/01.cir.85.2.627
PMID:1735157
Abstract

BACKGROUND

Thallium reinjection immediately after stress-redistribution imaging identifies ischemic but viable myocardium in as many as 50% of the regions characterized by conventional redistribution imaging as irreversibly injured. However, we have previously shown that some regions in which irreversible defects persist despite reinjection are metabolically active, and hence viable, by positron emission tomography. In the current study, we determined whether the severity of reduction in thallium activity within irreversible defects on redistribution images and the magnitude of change in regional thallium activity after reinjection can further discriminate viable from nonviable myocardium in such defects.

METHODS AND RESULTS

We studied 150 patients with coronary artery disease by exercise thallium tomography using the rest-reinjection protocol. The three sets of images (stress, redistribution, and reinjection) were then analyzed quantitatively. The increase in regional thallium activity from redistribution to reinjection was computed, normalized to the increase observed in a normal region, and termed "differential uptake." Of the 175 myocardial regions designated to have irreversible thallium defects on conventional 3-4 hour redistribution images, 132 had only mild-to-moderate reduction in thallium activity (51-85% of normal activity), and 43 had severe reduction in thallium activity (less than or equal to 50% of normal activity). Thallium reinjection resulted in enhanced relative activity in 60 of 132 (45%) of the mild-to-moderate irreversible defects and 22 of 43 (51%) of the severe irreversible defects, leaving roughly half of these defects remaining irreversible after reinjection. However, in regions that appeared to remain irreversible despite reinjection, the magnitude of differential uptake differed between mild-to-moderate (74 +/- 14%) and severe (35 +/- 16%) irreversible defects (p less than 0.001). All regions with mild-to-moderate defects demonstrated greater than 50% differential uptake after reinjection. In contrast, all except two of the regions with severe irreversible defects demonstrated differential uptake of less than 50%. Fifteen patients also underwent positron emission tomography at rest with 18F-fluorodeoxyglucose (FDG) and 15O-water. FDG uptake was present in 91% of regions with mild-to-moderate reduction in thallium activity, and the results of differential uptake and FDG data were concordant in 81% of these regions.

CONCLUSIONS

These data indicate that the magnitude of thallium uptake after reinjection differs between mild-to-moderate and severe irreversible defects on standard 3-4 hour redistribution images. The substantial differential uptake of thallium (greater than 50%) after reinjection in mild-to-moderate defects, even when relative thallium activity does not increase appreciably (and the defect appears to remain irreversible), coupled with preserved metabolic activity by positron emission tomography, supports the concept that such mild-to-moderate irreversible defects represent viable myocardium.

摘要

背景

负荷 - 再分布显像后立即进行铊再注射,可识别出在传统再分布显像中被判定为不可逆损伤的区域中多达50%的缺血但存活的心肌。然而,我们之前已经表明,尽管再注射后仍存在不可逆缺损的一些区域,通过正电子发射断层扫描显示其代谢活跃,因此是存活的。在本研究中,我们确定了再分布图像上不可逆缺损内铊活性降低的严重程度以及再注射后区域铊活性的变化幅度是否能进一步区分此类缺损中存活与非存活的心肌。

方法与结果

我们采用静息 - 再注射方案,通过运动铊断层扫描研究了150例冠心病患者。然后对三组图像(负荷、再分布和再注射)进行定量分析。计算从再分布到再注射区域铊活性的增加量,并将其归一化到正常区域观察到的增加量,称为“差异摄取”。在传统的3 - 4小时再分布图像上被判定为有不可逆铊缺损的175个心肌区域中,132个区域的铊活性仅有轻度至中度降低(为正常活性的51% - 85%),43个区域的铊活性严重降低(小于或等于正常活性的50%)。铊再注射使132个轻度至中度不可逆缺损中的60个(45%)和43个严重不可逆缺损中的22个(51%)的相对活性增强,再注射后这些缺损中约一半仍为不可逆。然而,在尽管再注射后仍似乎为不可逆的区域中,轻度至中度(74±14%)和严重(35±16%)不可逆缺损的差异摄取幅度不同(p<0.001)。所有轻度至中度缺损的区域在再注射后差异摄取均大于50%。相比之下,除两个区域外,所有严重不可逆缺损的区域差异摄取均小于50%。15例患者还在静息状态下接受了18F - 氟脱氧葡萄糖(FDG)和15O - 水的正电子发射断层扫描。铊活性轻度至中度降低的区域中91%存在FDG摄取,这些区域中81%的差异摄取结果与FDG数据一致。

结论

这些数据表明,在标准的3 - 4小时再分布图像上,轻度至中度和严重不可逆缺损再注射后铊摄取的幅度不同。轻度至中度缺损再注射后铊的大量差异摄取(大于50%),即使相对铊活性没有明显增加(且缺损似乎仍为不可逆),再加上正电子发射断层扫描显示的代谢活性保留,支持了这样一种观点,即此类轻度至中度不可逆缺损代表存活心肌。

相似文献

1
Regional thallium uptake in irreversible defects. Magnitude of change in thallium activity after reinjection distinguishes viable from nonviable myocardium.不可逆性缺损区域的铊摄取情况。再次注射后铊活性的变化幅度可区分存活心肌与无存活心肌。
Circulation. 1992 Feb;85(2):627-34. doi: 10.1161/01.cir.85.2.627.
2
Concordance and discordance between stress-redistribution-reinjection and rest-redistribution thallium imaging for assessing viable myocardium. Comparison with metabolic activity by positron emission tomography.用于评估存活心肌的负荷-再分布-再注射与静息-再分布铊显像之间的一致性和不一致性。与正电子发射断层扫描代谢活性的比较。
Circulation. 1993 Sep;88(3):941-52. doi: 10.1161/01.cir.88.3.941.
3
Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose.慢性冠状动脉疾病和左心室功能障碍患者存活心肌的识别。铊再注射闪烁扫描术与18F-氟脱氧葡萄糖PET成像的比较。
Circulation. 1991 Jan;83(1):26-37. doi: 10.1161/01.cir.83.1.26.
4
Myocardial viability in patients with chronic coronary artery disease. Comparison of 99mTc-sestamibi with thallium reinjection and [18F]fluorodeoxyglucose.慢性冠状动脉疾病患者的心肌存活性。99mTc-司他米比与铊再注射及[18F]氟脱氧葡萄糖的比较。
Circulation. 1994 Feb;89(2):578-87. doi: 10.1161/01.cir.89.2.578.
5
Regional left ventricular wall thickening. Relation to regional uptake of 18fluorodeoxyglucose and 201Tl in patients with chronic coronary artery disease and left ventricular dysfunction.局部左心室壁增厚。与慢性冠状动脉疾病和左心室功能障碍患者局部18氟脱氧葡萄糖和201铊摄取的关系。
Circulation. 1992 Oct;86(4):1125-37. doi: 10.1161/01.cir.86.4.1125.
6
Differential uptake and apparent 201Tl washout after thallium reinjection. Options regarding early redistribution imaging before reinjection or late redistribution imaging after reinjection.
Circulation. 1992 Mar;85(3):1032-8. doi: 10.1161/01.cir.85.3.1032.
7
Thallium reinjection after stress-redistribution imaging. Does 24-hour delayed imaging after reinjection enhance detection of viable myocardium?
Circulation. 1991 Apr;83(4):1247-55. doi: 10.1161/01.cir.83.4.1247.
8
Thallium reinjection demonstrates viable myocardium in regions with reverse redistribution.铊再注射显示在出现反向再分布的区域有存活心肌。
Circulation. 1993 Oct;88(4 Pt 1):1736-45. doi: 10.1161/01.cir.88.4.1736.
9
Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging.负荷-再分布显像后再注射铊增强对缺血但存活心肌的检测。
N Engl J Med. 1990 Jul 19;323(3):141-6. doi: 10.1056/NEJM199007193230301.
10
Identification of viable myocardium in patients with chronic coronary artery disease: comparison of thallium-201 scintigraphy with reinjection and technetium-99m-methoxyisobutyl isonitrile.慢性冠状动脉疾病患者存活心肌的识别:铊-201再注射闪烁显像与锝-99m-甲氧基异丁基异腈的比较
J Nucl Med. 1992 Apr;33(4):505-11.

引用本文的文献

1
Assessment of myocardial viability using F-18 fluorodeoxyglucose/Tc-99m sestamibi dual-isotope simultaneous acquisition SPECT: comparison with Tl-201 stress-reinjection SPECT.使用F-18氟脱氧葡萄糖/Tc-99m司他米比双同位素同步采集单光子发射计算机断层显像评估心肌存活:与Tl-201负荷再注射单光子发射计算机断层显像的比较
J Nucl Cardiol. 2005 Jul-Aug;12(4):451-9. doi: 10.1016/j.nuclcard.2005.04.007.
2
The historical and conceptual evolution of radionuclide assessment of myocardial viability.心肌存活放射性核素评估的历史与概念演变
J Nucl Cardiol. 2004 May-Jun;11(3):318-34. doi: 10.1016/j.nuclcard.2004.03.030.
3
Tl-201 reinjection enhances the detection of myocardial ischemia after acute myocardial infarction.
J Nucl Cardiol. 2003 Mar-Apr;10(2):117-20. doi: 10.1067/mnc.2003.20.
4
Metabolic imaging and contractile reserve for assessment of myocardial viability: friends or foes?用于评估心肌存活的代谢成像和收缩储备:是友还是敌?
J Nucl Cardiol. 1999 Jul-Aug;6(4):458-61. doi: 10.1016/s1071-3581(99)90012-0.
5
Combined assessment of left ventricular function and rest-redistribution regional myocardial thallium-201 activity for prognostic evaluation of patients with chronic coronary artery disease and left ventricular dysfunction.联合评估左心室功能及静息-再分布区域心肌铊-201活性以对慢性冠状动脉疾病合并左心室功能障碍患者进行预后评估。
J Nucl Cardiol. 1998 Jul-Aug;5(4):378-86. doi: 10.1016/s1071-3581(98)90143-x.
6
Exercise-induced ST-segment changes permit prediction of improvement in left ventricular ischemic dysfunction after revascularization: evaluation with positron emission tomographic measurements of regional myocardial blood flow and cardiac output.运动诱发的ST段改变可预测血运重建后左心室缺血性功能障碍的改善:通过正电子发射断层扫描测量局部心肌血流量和心输出量进行评估。
J Nucl Cardiol. 1998 May-Jun;5(3):256-64. doi: 10.1016/s1071-3581(98)90127-1.
7
Early postexercise thallium-201 reinjection after sublingual nitroglycerin augmentation: effects on detection of myocardial ischemia and/or viability.舌下含服硝酸甘油增强后运动后早期铊-201再注射:对心肌缺血和/或存活检测的影响
Clin Cardiol. 1998 Jun;21(6):419-26. doi: 10.1002/clc.4960210610.
8
Are technetium-99m-labeled myocardial perfusion agents adequate for detection of myocardial viability?锝-99m标记的心肌灌注剂是否足以检测心肌存活?
Clin Cardiol. 1998 Apr;21(4):235-42. doi: 10.1002/clc.4960210402.
9
Comparison of technetium 99m-tetrofosmin and thallium-201 single photon emission computed tomographic imaging for the assessment of viable myocardium in patients with left ventricular dysfunction.锝99m-替曲膦与铊201单光子发射计算机断层成像用于评估左心室功能不全患者存活心肌的比较。
J Nucl Cardiol. 1998 Jan-Feb;5(1):56-63. doi: 10.1016/s1071-3581(98)80011-1.
10
Thallium 201 for detection of viable myocardium: comparison of different reinjection protocols.用于检测存活心肌的铊201:不同再注射方案的比较
J Nucl Cardiol. 1994 Nov-Dec;1(6):515-21. doi: 10.1007/BF02939974.